Nemonoxacin malate has been approved for registration as an active pharmaceutical ingredient in marketed pharmaceutical preparations.
November 2, 2026
Source: drugdu
31
Nanfang Finance News, October 29th - Shijiazhuang Pharmaceutical Group (02005.HK) issued a voluntary announcement stating that the Group's Apple...Nemonoxacin acid has been approved and registered by the China National Medical Products Administration as an active pharmaceutical ingredient for use in marketed formulations.Nemonoxacin malate is an anti-infective drug primarily used to treat community-acquired pneumonia in adults.
Source: https://finance.eastmoney.com/a/202610293914204963.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Wolwo Pharma’s S01D Tablet Approved for Clinical Trials, a New-Mechanism Drug for Drug-Resistant Pulmonary Tuberculosis November 2, 2026
- Two specifications of dexketoprofen tromethamine tablets from Keruide Pharmaceuticals have been approved November 2, 2026
- Another domestically produced biopharmaceutical has entered the European market; Qilu Pharmaceutical’s bevacizumab has been shipped to the UK. November 2, 2026
- Vitamin B12 injection passes generic drug consistency evaluation November 2, 2026
- Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting October 29, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
